BioCentury
ARTICLE | Clinical News

Reolysin pelareorep regulatory update

May 11, 2015 7:00 AM UTC

The European Commission and FDA granted Orphan Drug designation to Reolysin pelareorep from Oncolytics to treat pancreatic cancer and gastric cancer, respectively. The formulation of human reovirus ty...